Citations (75)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Eva Van den Eynde & Daniel Podzamczer. (2014) Switch strategies in antiretroviral therapy regimens. Expert Review of Anti-infective Therapy 12:9, pages 1055-1074.
Read now
Read now
Thomas Rampling & Mark Nelson. (2011) Clinical utility and long-term use of atazanavir in the treatment of HIV-1 infection. Virus Adaptation and Treatment 3, pages 25-34.
Read now
Read now
Miguel Ángel Artacho, Pablo Barreiro & José Vicente Fernández-Montero. (2010) Long-term treatment of patients with HIV-1: the role of atazanavir. HIV/AIDS - Research and Palliative Care 2, pages 157-166.
Read now
Read now
Pablo Rivas, Judit Morello, Carolina Garrido, Sonia Rodríguez-Nóvoa & Vincent Soriano. (2009) Role of atazanavir in the treatment of HIV infection. Therapeutics and Clinical Risk Management 5, pages 99-116.
Read now
Read now
José Vicente Fernández-Montero, Pablo Barreiro & Vicente Soriano. (2009) HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opinion on Pharmacotherapy 10:10, pages 1615-1629.
Read now
Read now
M.G.A. van Vonderen, L. Gras, F. Wit, K. Brinkman, M.E. van der Ende, A.I.M. Hoepelman, F. de Wolf & P. Reiss. (2009) Baseline Lipid Levels Rather Than the Presence of Reported Body Shape Changes Determine the Degree of Improvement in Lipid Levels After Switching to Atazanavir. HIV Clinical Trials 10:3, pages 168-180.
Read now
Read now
José Ramón Santos, José Moltó, Josep Maria Llibre, Nuria Pérez, Mari Carmen Capitán, Cristina Miranda & Bonaventura Clotet. (2009) Unboosted Atazanavir Plus Co-formulated Lamivudine/Abacavir as a Ritonavir-Sparing Simplification Strategy in Routine Clinical Practice. HIV Clinical Trials 10:3, pages 129-134.
Read now
Read now
Ashish Chandwani & Jonathan Shuter. (2008) Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Therapeutics and Clinical Risk Management 4:5, pages 1023-1033.
Read now
Read now
Robin Wood. (2008) Atazanavir: its role in HIV treatment. Expert Review of Anti-infective Therapy 6:6, pages 785-796.
Read now
Read now
Kristin H Busse & Scott R Penzak. (2008) Pharmacological enhancement of protease inhibitors with ritonavir: an update. Expert Review of Clinical Pharmacology 1:4, pages 533-545.
Read now
Read now
Meena Lagnese & Eric S Daar. (2008) Antiretroviral regimens for treatment-experienced patients with HIV-1 infection. Expert Opinion on Pharmacotherapy 9:5, pages 687-700.
Read now
Read now
María Jesús Pérez-Elías. (2007) Atazanavir: simplicity and convenience in different scenarios. Expert Opinion on Pharmacotherapy 8:5, pages 689-700.
Read now
Read now
Articles from other publishers (63)
KuldeepKumar Ashta, Sumit Arora & Niket Verma. (2022) Outcomes in HIV patients on two different protease inhibitors on second-line antiretroviral therapy: An observational study. Journal of Marine Medical Society 24:2, pages 113.
Crossref
Crossref
Jeremy Nel, Sipho Dlamini, Graeme Meintjes, Rosie Burton, John M. Black, Natasha E.C.G. Davies, Eric Hefer, Gary Maartens, Phetho M. Mangena, Moeketsi T. Mathe, Mahomed-Yunus Moosa, Muhangwi B. Mulaudzi, Michelle Moorhouse, Jennifer Nash, Thandeka C. Nkonyane, Wolfgang Preiser, Mohammed S. Rassool, David Stead, Helen van der Plas, Cloete van Vuuren, Willem D.F. Venter & Joana F. Woods. (2020) Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. Southern African Journal of HIV Medicine 21:1.
Crossref
Crossref
Xiaojie Huang, Liumei Xu, Lijun Sun, Guiju Gao, Weiping Cai, Yanfen Liu, Haibo Ding, Hongxia Wei, Ping Ma, Min Wang, Shuiqing Liu, Yaokai Chen, Xiaohong Chen, Qingxia Zhao, Jianhua Yu, Yuxia Song, Hui Chen, Hao Wu, Shanfang Qin & Linghua Li. (2019) Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China. Frontiers in Pharmacology 10.
Crossref
Crossref
Esther Muya & Appolinary Kamuhabwa. (2019) Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs. Journal of the International Association of Providers of AIDS Care (JIAPAC) 18, pages 232595821984190.
Crossref
Crossref
Yinqiu Huang, Xiaojie Huang, Yadong Luo, Yihong Zhou, Xingbao Tao, Hui Chen, Aixin Song, Yaokai Chen & Hao Wu. (2018) Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations. Frontiers in Pharmacology 9.
Crossref
Crossref
Steve Kanters, Maria Eugenia Socias, Nicholas I Paton, Marco Vitoria, Meg Doherty, Dieter Ayers, Evan Popoff, Keith Chan, David A Cooper, Matthew O Wiens, Alexandra Calmy, Nathan Ford, Sabin Nsanzimana & Edward J Mills. (2017) Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. The Lancet HIV 4:10, pages e433-e441.
Crossref
Crossref
Annemarie M. J. Wensing, Axel Fun & Monique Nijhuis. 2017. Handbook of Antimicrobial Resistance. Handbook of Antimicrobial Resistance
567
602
.
Tim R. Cressey, Rohan Hazra, Andrew Wiznia, Marc Foca, Patrick Jean-Philippe, Bobbie Graham, Jennifer R. King, Paula Britto, Vincent J. Carey, Edward P. Acosta & Ram Yogev. (2016) Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults. Pediatric Infectious Disease Journal 35:12, pages 1333-1335.
Crossref
Crossref
Josefin Koehn, Yue Ding, Jennifer Freeling, Jinghua Duan & Rodney J. Y. Ho. (2015) A Simple, Efficient, and Sensitive Method for Simultaneous Detection of Anti-HIV Drugs Atazanavir, Ritonavir, and Tenofovir by Use of Liquid Chromatography-Tandem Mass Spectrometry. Antimicrobial Agents and Chemotherapy 59:11, pages 6682-6688.
Crossref
Crossref
Xiaojie Huang, Yuanlong Xu, Qiuying Yang, Jieqing Chen, Tong Zhang, Zaicun Li, Caiping Guo, Hui Chen, Hao Wu & Ning Li. (2015) Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials. Scientific Reports 5:1.
Crossref
Crossref
Richard M. Rutstein, Pearl Samson, Terry Fenton, Courtney V. Fletcher, Jennifer J. Kiser, Lynne M. Mofenson, Elizabeth Smith, Bobbie Graham, Marina Mathew & Grace Aldrovani. (2015) Long-term Safety and Efficacy of Atazanavir-based Therapy in HIV-infected Infants, Children and Adolescents. Pediatric Infectious Disease Journal 34:2, pages 162-167.
Crossref
Crossref
Catherine Orrell, Franco Felizarta, André Nell, Thomas N. Kakuda, Ludo Lavreys, Steven Nijs, Lotke Tambuyzer, Rodica Van Solingen-Ristea & Frank L. Tomaka. (2015) Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients. AIDS Research and Treatment 2015, pages 1-11.
Crossref
Crossref
Thomas S. MetkusJr.Jr., Todd T. Brown & Wendy S. Post. (2014) Cardiovascular Disease Associated with the Human Immunodeficiency Virus: An Update. Current Treatment Options in Cardiovascular Medicine 16:11.
Crossref
Crossref
Jinghua Duan, Jennifer P. Freeling, Josefin Koehn, Cuiling Shu & Rodney J.Y. Ho. (2014) Evaluation of Atazanavir and Darunavir Interactions with Lipids for Developing pH-Responsive Anti-HIV Drug Combination Nanoparticles. Journal of Pharmaceutical Sciences 103:8, pages 2520-2529.
Crossref
Crossref
María Inés Figueroa, Omar Sued & Pedro Cahn. (2014) What to do Next? Second-line Antiretroviral Therapy. Current Treatment Options in Infectious Diseases 6:2, pages 159-170.
Crossref
Crossref
Suman Srinivasa & Steven K Grinspoon. (2014) MECHANISMS IN ENDOCRINOLOGY: Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. European Journal of Endocrinology 170:5, pages R185-R202.
Crossref
Crossref
J Baril, B Conway, P Giguère, N Ferko, S Hollmann & JB Angel. (2014) A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction. HIV Medicine 15:5, pages 301-310.
Crossref
Crossref
Annemarie M. J. Wensing, Axel Fun & Monique Nijhuis. 2014. Handbook of Antimicrobial Resistance. Handbook of Antimicrobial Resistance
1
31
.
Changfu Cheng, Sunanda Vedananda, Lijun Wu, Scott Harbeson, Virginia Braman & Roger Tung. (2013) Revealing the metabolic sites of atazanavir in human by parallel administrations of D‐atazanavir analogs. Journal of Mass Spectrometry 48:9, pages 1019-1031.
Crossref
Crossref
Changfu Cheng, Richard Gallegos, Gary Bridson, Lijun Wu, Scott Harbeson, Robert Zelle & Roger Tung. (2013)
Identification and structural elucidation of
in vitro
metabolites of atazanavir by HPLC and tandem mass spectrometry
. Journal of Mass Spectrometry 48:6, pages 640-650.
Crossref
Crossref
E Seminari, A De Silvestri, L Scudeller, V Scotti & C Tinelli. (2012) Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities. International Journal of STD & AIDS 23:12, pages 837-842.
Crossref
Crossref
J.R. Bogner. (2012) HIV-InfektionHIV infection. Der Internist 53:10, pages 1169-1178.
Crossref
Crossref
Colleen M. Wegzyn, Linda M. Fredrick, Roxann O. Stubbs, William C. Woodward & Michael Norton. (2012) Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy. Journal of the International Association of Physicians in AIDS Care 11:4, pages 252-259.
Crossref
Crossref
Emanuele Focà, Diego Ripamonti, Davide Motta & Carlo Torti. (2012) Unboosted Atazanavir for Treatment of HIV Infection. Drugs 72:9, pages 1161-1173.
Crossref
Crossref
Luz Martín-CarboneroVicente Soriano. (2012) Long-Term Use of Atazanavir in the Treament of HIV-Infected patients. Clinical Medicine Insights: Therapeutics 4, pages CMT.S5764.
Crossref
Crossref
Awny Farajallah, R. Todd Bunch & Nicholas A. Meanwell. 2011. Antiviral Drugs. Antiviral Drugs
1
17
.
Fenglei Huang, Paul Scholl, David B. Huang, Thomas R. MacGregor, Richard Vinisko, Mark A. Castles, Frank Berger & Patrick Robinson. (2013) Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. The Journal of Clinical Pharmacology 51:7, pages 1061-1070.
Crossref
Crossref
Mario Ferreira Peixoto, José Henrique Pilotto, Sonia Karolina Stoszek, Regis Kreitchmann, Marisa Márcia Mussi-Pinhata, Victor Hugo Melo, Esaú Custodio João, Mariana Ceriotto, Ricardo da Silva de Souza & Jennifer Read. (2011) Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities. The Brazilian Journal of Infectious Diseases 15:3, pages 253-261.
Crossref
Crossref
Chad J Achenbach, Kristin M Darin, Robert L Murphy & Christine Katlama. (2011) Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virology 6:2, pages 157-177.
Crossref
Crossref
Luc de Saint-Martin, Luc Bressollette, Pascale Perfezou, Véronique Bellein, Séverine Ansart, Sophie Vallet & Elisabeth Pasquier. (2010) Impact of atazanavir-based HAART regimen on the carotid intima–media thickness of HIV-infected persons: a comparative prospective cohort. AIDS 24:18, pages 2797-2801.
Crossref
Crossref
Michael PfallerSarah Pett & Sean Emery. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
2830
2841
.
Julian H. Elliott. (2010) Second line antiretroviral therapy for treatment of HIV in Asia. Asian Biomedicine 4:5, pages 673-677.
Crossref
Crossref
Jamie D. Croxtall & Caroline M. Perry. (2010) Lopinavir/Ritonavir. Drugs 70:14, pages 1885-1915.
Crossref
Crossref
A. Curran, M. Gutirerrez, E. Deig, G. Mateo, R. M. Lopez, A. Imaz, M. Crespo, I. Ocana, P. Domingo & E. Ribera. (2010) Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. Journal of Antimicrobial Chemotherapy 65:10, pages 2195-2203.
Crossref
Crossref
D. Carey, J. Amin, M. Boyd, K. Petoumenos & S. Emery. (2010) Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy 65:9, pages 1878-1888.
Crossref
Crossref
Arun K. Ghosh & Bruno D. Chapsal. 2010. Aspartic Acid Proteases as Therapeutic Targets. Aspartic Acid Proteases as Therapeutic Targets
169
204
.
François-Xavier Lescure, Jean-Marie Poirier, Jean-Luc Meynard, Jean-Baptiste Guiard-Schmid, Ouahiba Zouai, Philippe Bonnard, Laurence Slama, Corinne Amiel, Pierre-Marie Girard & Gilles Pialoux. (2010) Factors predictive of virological failure on atazanavir in 310 HIV-infected patients. AIDS 24:10, pages 1593-1595.
Crossref
Crossref
Annemarie M.J. Wensing, Noortje M. van Maarseveen & Monique Nijhuis. (2010) Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Research 85:1, pages 59-74.
Crossref
Crossref
Benjamin P Linas, Elena Losina, Annette Rockwell, Rochelle P Walensky, Kevin Cranston & Kenneth A Freedberg. (2009) Improving Outcomes in State AIDS Drug Assistance Programs. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:5, pages 513-521.
Crossref
Crossref
Katherine F. Croom, Sohita Dhillon & Susan J. Keam. (2009) Atazanavir. Drugs 69:8, pages 1107-1140.
Crossref
Crossref
Clotilde AllavenaStéphanie TrancartLise Cuzin. (2009) Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults. Clinical Medicine. Therapeutics 1, pages CMT.S1088.
Crossref
Crossref
Paul A. Pham & Charles W. Flexner. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics
1187
1199
.
Kimberly Smith & Rafael Campo. 2009. HIV/AIDS in U.S. Communities of Color. HIV/AIDS in U.S. Communities of Color
33
51
.
Shannon Schrader, Susan K Chuck, Laurie W Rahn, Paras Parekh & Katherine G Emrich. (2008) Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules. AIDS Research and Therapy 5:1.
Crossref
Crossref
Esteban Ribera Pascuet & Adrià Curran. (2008) Utilidad clínica de atazanavir. Enfermedades Infecciosas y Microbiología Clínica 26, pages 55-67.
Crossref
Crossref
Julian H Elliott & Sanjay Pujari. (2008) Protease inhibitor therapy in resource-limited settings. Current Opinion in HIV and AIDS 3:6, pages 612-619.
Crossref
Crossref
Andrew Hill & Caroline Sabin. (2008) Designing and interpreting HIV noninferiority trials in naive and experienced patients. AIDS 22:8, pages 913-921.
Crossref
Crossref
Andrew N Phillips, Andrew Carr, Jacquie Neuhaus, Fehmida Visnegarwala, Ronald Prineas, William J Burman, Ian Williams, Fraser Drummond, Daniel Duprez, Waldo H Belloso, Frank-Detlef Goebel, Birgit Grund, Angelos Hatzakis, Jose Vera & Jens D Lundgren. (2008) Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial. Antiviral Therapy 13:2, pages 177-188.
Crossref
Crossref
Caroline A Sabin. (2008) Cardiovascular risk and choice of HIV drug regimen. Future HIV Therapy 2:1, pages 83-92.
Crossref
Crossref
Maria Mercedes SantoroAda BertoliPatrizia LorenziniAdriano LazzarinRoberto EspositoGiampiero CarosiGiovanni Di PerriGaetano FiliceMauro MoroniGiuliano RizzardiniPietro CaramelloRenato MaseratiPasquale NarcisoAntonietta CargnelAndrea AntinoriCarlo Federico Perno. (2008) Viro-Immunologic Response to Ritonavir-Boosted or Unboosted Atazanavir in a Large Cohort of Multiply Treated Patients: The CARe Study. AIDS Patient Care and STDs 22:1, pages 7-16.
Crossref
Crossref
Edward P. Acosta, Michelle A. Kendall, John G. Gerber, Beverly Alston-Smith, Susan L. Koletar, Andrew R. Zolopa, Sangeeta Agarwala, Michael Child, Richard Bertz, Lara Hosey & David W. Haas. (2007) Effect of Concomitantly Administered Rifampin on the Pharmacokinetics and Safety of Atazanavir Administered Twice Daily. Antimicrobial Agents and Chemotherapy 51:9, pages 3104-3110.
Crossref
Crossref
David Isaacs, Elizabeth Elliott, Ruth Gilbert, Virginia Moyer & Michael Pichichero. 2007. Evidence‐based Pediatric Infectious Diseases. Evidence‐based Pediatric Infectious Diseases
102
116
.
Justin Stebbing, Bif Nathan, Rachael Jones, Alex McKenna, Tom Powles, Mark Bower, Paul Holmes, Brian Gazzard & Mark Nelson. (2007) Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. AIDS 21:13, pages 1826-1828.
Crossref
Crossref
J. Gatell, D. S. Ceron, A. Lazzarin, E. V. Wijngaerden, F. Antunes, C. Leen, A. Horban, V. Wirtz, L. Odeshoo, M. V. d. Dungen, C. Gruber & E. Ledesma. (2007) Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results. Clinical Infectious Diseases 44:11, pages 1484-1492.
Crossref
Crossref
F Josephson, A Allqvist, M Janabi, J Sayi, E Aklillu, M Jande, M Mahindi, J Burhenne, Y Bottiger, L L Gustafsson, W E Haefeli & L Bertilsson. (2007) CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir. Clinical Pharmacology & Therapeutics 81:5, pages 708-712.
Crossref
Crossref
Judith C Shlay, Glenn Bartsch, Grace Peng, Jack Wang, Carl Grunfeld, Cynthia L Gibert, Fehmida Visnegarwala, Sai Subhasree Raghavan, Ying Xiang, Martha Farrough, Harold E Perry, Donald Kotler & Wafaa M El-Sadr. (2007) Long-Term Body Composition and Metabolic Changes in Antiretroviral Naive Persons Randomized to Protease Inhibitor-, Nonnucleoside Reverse Transcriptase Inhibitor-, or Protease Inhibitor Plus Nonnucleoside Reverse Transcriptase Inhibitor-Based Strategy. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:5, pages 506-517.
Crossref
Crossref
Brian P Kearney, Anita Mathias, Angelique Mittan, John Sayre, Ramin Ebrahimi & Andrew K Cheng. (2006) Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir. JAIDS Journal of Acquired Immune Deficiency Syndromes 43:3, pages 278-283.
Crossref
Crossref
Todd T. Brown & Joseph CofrancescoJrJr. (2006) Metabolic abnormalities in HIV-infected patients: An update. Current Infectious Disease Reports 8:6.
Crossref
Crossref
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
Esteban Ribera, Carlos Azuaje, Rosa M Lopez, Marjorie Diaz, Maria Feijoo, Leonor Pou, Manuel Crespo, Adria Curran, Imma Ocaña & Albert Pahissa. (2006) Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 20:8, pages 1131-1139.
Crossref
Crossref
J Stebbing, M Bower, P Holmes, B Gazzard & M Nelson. (2006) A single centre cohort experience with a new once daily antiretroviral drug. Postgraduate Medical Journal 82:967, pages 343-346.
Crossref
Crossref
Christophe Piketty, Laurence Gérard, Corine Chazallon, Anne-Geneviève Marcelin, François Clavel, Anne-Marie Taburet, Vincent Calvez, Isabelle Madelaine-Chambrin, Jean-Michel Molina, Jean-Pierre Aboulker & Pierre-Marie Girard. (2006) Salvage Therapy with Atazanavir/Ritonavir Combined to Tenofovir in HIV-Infected Patients with Multiple Treatment Failures: Randomized Anrs 107 Trial. Antiviral Therapy 11:2, pages 213-222.
Crossref
Crossref
Vicki Oldfield & Greg L Plosker. (2006) Lopinavir/Ritonavir. Drugs 66:9, pages 1275-1299.
Crossref
Crossref